A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are:
- To determine the safety and the maximum tolerated dose (MTD) of IPI-926
- To examine the pharmacokinetic parameters of IPI-926 and its characterized major
metabolite(s)
- To recommend a dose and schedule of IPI-926 for subsequent studies